Novartis Ag (NVS) Free Cash Flow (2009 - 2026)
Novartis Ag (NVS) posted Free Cash Flow of $5.6 billion for Q2 2026, up 1507.23% sequentially from $346.0 million in Q1 2026, and down 12.19% YoY from $6.3 billion in Q2 2025.
Novartis Ag (NVS) Free Cash Flow (2009 - 2026) Analysis & Trends
Novartis Ag has reported Free Cash Flow for 18 years, with the latest figure at $5.6 billion in Q2 2026.
- Quarterly Free Cash Flow fell 12.19% year-over-year to $5.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $6.9 billion (down 52.96% YoY) and the FY2025 annual result came in at $17.6 billion, up 8.26% from the prior year.
- Free Cash Flow improved to $5.6 billion in Q2 2026 per NVS's latest filing, from $346.0 million in the prior quarter.
- Over five years, Free Cash Flow peaked at $7.7 billion in Q4 2024 and troughed at $168.0 million in Q1 2023.
- A 5-year average of $2.0 billion and a median of $350.0 million in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2025: Free Cash Flow jumped 1796.06% in 2024, then tumbled 92.09% in 2025.
- Over 5 years, Free Cash Flow stood at $306.0 million in 2022, then soared by 32.68% to $406.0 million in 2023, then surged by 1796.06% to $7.7 billion in 2024, then sank by 92.09% to $609.0 million in 2025, then soared by 813.14% to $5.6 billion in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered $5.6 billion, $346.0 million, and $609.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 7.30 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 3.11 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 4.48 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.56 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 3.49 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 3.43 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 302.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 440.07 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 2.55 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.56 Bn |
| Jun 30, 2026 | 5.56 Bn |
| Mar 31, 2026 | 346.00 Mn |
| Mar 31, 2026 | 346.00 Mn |
| Dec 31, 2025 | 609.00 Mn |
| Dec 31, 2025 | 609.00 Mn |
| Sep 30, 2025 | 354.00 Mn |
| Sep 30, 2025 | 354.00 Mn |
| Jun 30, 2025 | 6.33 Bn |
| Jun 30, 2025 | 6.33 Bn |
| Mar 31, 2025 | 254.00 Mn |
| Mar 31, 2025 | 254.00 Mn |
| Dec 31, 2024 | 7.70 Bn |
| Dec 31, 2024 | 7.70 Bn |
| Sep 30, 2024 | 321.00 Mn |
| Sep 30, 2024 | 321.00 Mn |
| Jun 30, 2024 | 5.14 Bn |
| Jun 30, 2024 | 5.14 Bn |
| Mar 31, 2024 | 227.00 Mn |
| Mar 31, 2024 | 227.00 Mn |